Status:

COMPLETED

Safety and Immune Enhancing Effects of Acute Dosing of COLD-fX in Healthy Adults

Lead Sponsor:

CV Technologies

Conditions:

Healthy

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

Subjects will be asked to participate in a four day research study of the immune system effects and safety of short-term acute dosing of Cold-fX. The purpose of the study is to determine the effects ...

Detailed Description

Eligible volunteers from Hackensack University Medical Centre will be randomly assigned to either the treatment or placebo group with equal numbers in each group. The treatment will consist of taking...

Eligibility Criteria

Inclusion

  • General good health
  • Willing to adhere to the requirements of the protocol, including availability for follow-up visits
  • Willing and able to sign written informed consent

Exclusion

  • Individuals with known HIV infection
  • Individuals with malignancy
  • Individuals with a history or symptoms of unstable cardiovascular disease
  • Individuals with renal abnormalities
  • Individuals having a history or symptoms of pulmonary disease
  • Individuals having acute or active chronic liver disease
  • Individuals having neurologic or psychiatric disease
  • Individuals having active tuberculosis
  • Individuals having multiple sclerosis
  • Individuals having bleeding disorders
  • Individuals with planned surgery over the course of the trial or having had major surgery in the past 6 mo.
  • Individuals with a history of alcohol/drug abuse
  • Pregnant and lactating women
  • Individuals on prescribed medication with the exception of oral contraceptives
  • Individuals with Crohn's disease, Lupus, Rheumatoid arthritis, Colitis or any other auto-immune disease
  • Individuals using natural health products or dietary supplements for 2 weeks prior and during the trial
  • Individuals having allergies to ginseng or to any known component of the drug product or placebo
  • Smokers (smoking \> 10 cigarettes/day)
  • Alcoholics (drinking \> 10 drinks/week)

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2007

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT00435968

Start Date

March 1 2007

End Date

July 1 2007

Last Update

July 17 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601